Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 11;18(1):48.
doi: 10.1007/s11657-023-01238-6.

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

Zaizhu Zhang  1 , Qiang Lin  2 , Ying Xu  1 , Wenmin Guan  3 , Xiaojing Song  4 , Yanling Li  4 , Yi Zhang  1 , Taisheng Li  5 , Wei Yu  6
Affiliations

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

Zaizhu Zhang et al. Arch Osteoporos. .

Abstract

This is the first study to report both greater BMD loss and muscle loss in Chinese HIV-infected males with lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV) regimen, which highlights the importance of closely monitoring muscle mass and bone mineral density in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis.

Purpose: To compare the effect initiating different antiretroviral therapy (ART) regimens have on muscle mass, bone mineral density (BMD), and trabecular bone score (TBS).

Methods: We designed a retrospective study of ART-naive Chinese males with HIV (MWH) undergoing two different regimens at 1-year follow-up. All subjects underwent dual-energy absorptiometry (DXA) for BMD and muscle mass prior to ART initiation, and again 1 year later. TBS iNsight software was used for TBS. We analyzed differences in muscle mass, BMD, and TBS after different treatment arms and associations between ART regimens and changes in them.

Results: A total of 76 men were included (mean age 31.83 ± 8.75 years). Mean absolute muscle mass decreased significantly from baseline to follow-up after initiation of lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV), whereas increased significantly after initiation of 3TC-zidovudine(AZT)/Stavudine(d4T)-Nevirapine(NVP). Assignment to 3TC-TDF-EFV resulted in greater percentage loss in BMD at lumbar spine (LS) and total hip (TH) compared to 3TC-AZT/d4T-NVP, but this difference was not statistically significant at the femoral neck BMD and TBS. In the multivariable logistic regression model adjusted for covariates, the 3TC-TDF-EFV regimen was associated with higher odds of decreased appendicular and total muscle mass, LS and TH BMD.

Conclusions: This is the first study to report not only greater BMD loss but also muscle loss in Chinese MWH with 3TC-TDF-EFV regimen. Our work highlights the importance of closely monitoring muscle mass and BMD in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis in them.

Keywords: Antiretroviral therapy (ART); Bone mineral density (BMD); Human immunodeficiency virus (HIV); Muscle mass; Trabecular bone score (TBS).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. New England J Med 338(13):853–860 - DOI
    1. Goh SSL, Lai PSM, Tan ATB et al (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis Int Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 29(3):595–613 - DOI
    1. Sax PE, Wohl D, Yin MT et al (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England) 385(9987):2606–2615 - DOI - PubMed
    1. Oliveira VHF, Borsari AL, Webel AR et al (2020) Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Eur J Clin Nutr 74(7):1009–1021 - DOI - PubMed
    1. Konishi K, Nakagawa H, Asaoka T et al (2022) Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine 101(42):e31349 - DOI - PubMed - PMC

Publication types

LinkOut - more resources